151 related articles for article (PubMed ID: 23955590)
1. Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity.
Pannucci NL; Li D; Sahay S; Thomas EK; Chen R; Tala I; Hu T; Ciccarelli BT; Megjugorac NJ; Adams Iii HC; Rodriguez PL; Fitzpatrick ER; Lagunoff D; Williams DA; Whitehead IP
Blood Cancer J; 2013 Aug; 3(8):e135. PubMed ID: 23955590
[TBL] [Abstract][Full Text] [Related]
2. Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
Ciccarelli BT; Hu T; Wang Q; Kim JJ; Whitehead IP
Leuk Res; 2020 Oct; 97():106440. PubMed ID: 32892149
[TBL] [Abstract][Full Text] [Related]
3. Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
Tala I; Chen R; Hu T; Fitzpatrick ER; Williams DA; Whitehead IP
Leukemia; 2013 Apr; 27(5):1080-9. PubMed ID: 23207522
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.
Chen R; Hu T; Mahon GM; Tala I; Pannucci NL; Ozer HL; Whitehead IP
Blood; 2013 Sep; 122(12):2114-24. PubMed ID: 23950177
[TBL] [Abstract][Full Text] [Related]
5. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation.
Canitrot Y; Falinski R; Louat T; Laurent G; Cazaux C; Hoffmann JS; Lautier D; Skorski T
Blood; 2003 Oct; 102(7):2632-7. PubMed ID: 12829601
[TBL] [Abstract][Full Text] [Related]
6. Validation of a
Outa AA; Abubaker D; Bazarbachi A; Sabban ME; Shirinian M; Nasr R
Haematologica; 2020; 105(2):387-397. PubMed ID: 31101753
[TBL] [Abstract][Full Text] [Related]
7. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
8. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.
Takeda N; Shibuya M; Maru Y
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):203-7. PubMed ID: 9874796
[TBL] [Abstract][Full Text] [Related]
9. Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage.
Järås M; Johnels P; Agerstam H; Lassen C; Rissler M; Edén P; Cammenga J; Olofsson T; Bjerrum OW; Richter J; Fan X; Fioretos T
Exp Hematol; 2009 Mar; 37(3):367-75. PubMed ID: 19135771
[TBL] [Abstract][Full Text] [Related]
10. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
[TBL] [Abstract][Full Text] [Related]
11. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
12. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
[TBL] [Abstract][Full Text] [Related]
14. BCR binds to the xeroderma pigmentosum group B protein.
Maru Y; Kobayashi T; Tanaka K; Shibuya M
Biochem Biophys Res Commun; 1999 Jul; 260(2):309-12. PubMed ID: 10403766
[TBL] [Abstract][Full Text] [Related]
15. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
16. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
[TBL] [Abstract][Full Text] [Related]
17. Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.
Lidonnici MR; Corradini F; Waldron T; Bender TP; Calabretta B
Blood; 2008 May; 111(9):4771-9. PubMed ID: 18227349
[TBL] [Abstract][Full Text] [Related]
18. Targeting BCL-2 as a Therapeutic Strategy for Primary
Massimino M; Tirrò E; Stella S; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Romeo MA; DI Raimondo F; Manzella L
In Vivo; 2020; 34(2):511-516. PubMed ID: 32111748
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
